A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy

被引：0

作者：

Uchida, Yoshiyasu ^{[1
]}

Ninomiya, Takashi ^{[1
]}

Harada, Daijiro ^{[1
]}

Kozuki, Toshiyuki ^{[1
]}

机构：

[1] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.05.126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO11-4

引用

页码：S488 / S488

页数：1

共 50 条

[11] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
da Silva, L. L.
Matsas, S.
Aguiar, P., Jr.
Taveira, G. M. T.
Barcelos, I. F.
Lopes, G. L., Jr.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
[12] The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases
Han, Huan
Tang, Hong
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[13] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Ramalingam, S. S.
Vansteenkiste, J.
Planchard, D.
Cho, B. C.
Gray, J. E.
Ohe, Y.
Zhou, C.
Reungwetwattana, T.
Cheng, Y.
Chewaskulyong, B.
Shah, R.
Cobo, M.
Lee, K. H.
Cheema, P.
Tiseo, M.
John, T.
Lin, M-C
Imamura, F.
Kurata, T.
Todd, A.
Hodge, R.
Saggese, M.
Rukazenkov, Y.
Soria, J-C
Boyer, Michael
Lee, Chee
Hughes, Brett
O'Byrne, Kenneth
Briggs, Peter
Milward, Michael
John, Thomas
Demedts, Ingel
Vansteenkiste, Johan
Bustin, Frederique
Barrios, Carlos Henrique
Timcheva, Constanta
Butts, Charles
Goss, Glenwood
Juergens, Rosalyn
Leighl, Natasha
Cheng, Susanna
Burkes, Ronald
Zhou, Caicun
Zhang, Helong
Shu, Yongqian
Cheng, Ying
Zhou, Qing
Li, Wei
Feng, Guosheng
He, Yong
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 41 - 50
[14] A Phase III Study of Rilertinib Versus Gefitinib as FirstLine Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC
Zhou, C.
Xiong, A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S11 - S11
[15] Recurrence of locally advanced NSCLC after radiochemotherapy and consolidative Durvalumab - A german multicenter retrospective analysis
Reitnauer, Lea
Evers, Georg
Christoph, Daniel
Brueckl, Wolfgang
Wiesweg, Marcel
Glanemann, Franziska
Webendoerfer, Maximilian
Kropf-Sanchen, Cornelia
Acker, Fabian
Schuette, Wolfgang
Hoffknecht, Petra
Kerkhoff, Andrea
Mohr, Michael
Lenz, Georg
Frost, Nikolaj
Overbeck, Tobias
Sebastian, Martin
Bleckmann, Annalen
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 135 - 136
[16] Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients
Nunes, D.
Dansin, E.
Lamblin, C.
Wasielewski, E.
Descarpentries, C.
Gregoire, V.
Copin, M. C.
Escande, F.
Cortot, A.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2237 - S2238
[17] Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
Ahn, Myung-Ju
Cho, Byoung Chul
Ou, Xiaoling
Walding, Andrew
Dymond, Angela W.
Ren, Song
Cantarini, Mireille
Janne, Pasi A.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) : 718 - 723
[18] Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
Li, Xingyuan
Huang, Huayan
Sun, Yingjia
Jiang, Qing
Yu, Yongfeng
FRONTIERS IN ONCOLOGY, 2023, 13
[19] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Julian Taugner
Lukas Käsmann
Chukwuka Eze
Alexander Rühle
Amanda Tufman
Niels Reinmuth
Thomas Duell
Claus Belka
Farkhad Manapov
Investigational New Drugs, 2021, 39 : 1189 - 1196
[20] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Taugner, Julian
Kaesmann, Lukas
Eze, Chukwuka
Ruehle, Alexander
Tufman, Amanda
Reinmuth, Niels
Duell, Thomas
Belka, Claus
Manapov, Farkhad
INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1189 - 1196

← 1 2 3 4 5 →